Recent Articles in News & Analysis

WuXi Biologics partnered with Medigene AG, a Munich Biotech, to design T cell receptor-guided T Cell Engagers (TCR-TCEs) aimed at difficult-to-treat tumors. The three-year effort will combine Medigen’s TCR expertise with WuXi’s anti-CD3 mAb, a TCE platform, and its proprietary bispecific antibody platform, WuXiBody™. Medigene wants to extend TCRs into new modalities, such as TCR-TCEs. The companies say the collaboration has the potential to become a multi-TCR program partnership. Wuxi Biologics is a Shanghai CRDMO focused on biologic drug development. More details....

Share this with colleagues:  

Huadong Medicine (Hangzhou) entered a $153 million pact for China commercialization rights to Immunopharm Technology’s IM19, a CAR T-cell immunotherapy that targets lymphoma. Huadong will pay $17.5 million upfront. IM19 injection has finished clinical trials for three indications, and Immunopharm expects to file for marketing approval before the end of the year. Immunopharm is a Beijing cell and gene therapy company. Huadong in-licenses China distribution rights for novel drugs. Previously, it acquired rights to commercialize a CARsgen CAR-T in China. More details....

Share this with colleagues:  

Sanyou Biopharmaceuticals (Shanghai), a CRMO, formed a collaboration agreement with Guangdong JiAnTeBo Biotechnology to discover and validate new antibody candidates. Sanyou Bio will use its antibody discovery platform to identify over 200 lead antibody drug molecules. JiAnTeBo will apply its cell activity detection system for functional testing of these molecules.  Using its technology, JiAnTeBo, has discovered new targets for metabolic diseases including obesity, fatty liver, diabetes, and Alzheimer's disease. The company is developing mRNA and agonist antibody drugs. More details....

Share this with colleagues:  

Beijing Genor Biopharma granted a global license (ex-China) for its CD20/CD3 bispecific as a therapy for autoimmune diseases to TRC 2004, a new company backed by Third Rock Ventures. Genor has already conducted a China-Australia Phase I/II trial of the candidate in patients with B-NHL. GB261 is a novel CD20/CD3 bispecific T-Cell Engager (TCE) with ultra-low CD3 binding affinity and full Fc functionality. Genor will receive equity in TRC 2004, an upfront payment of double-digit-millions of dollars, milestones of up to $443 million and royalties on sales. More details....

Share this with colleagues:  

Daiichi Sankyo will co-develop Merck’s MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager. Merck acquired the candidate when it bought Harpoon Therapeutics in January for $670 million. Merck will receive an upfront payment of $170 million from Daiichi Sankyo; development costs and sales revenues will be split between the two companies. In 2023, Merck formed an agreement for joint development of three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates. Merck paid $4 billion upfront in the deal which had a total value of $22 billion. More details....

Share this with colleagues: